Assessment of the Safety of Olmesartan in Combination with Sorafenib in Mice Bearing Ehrlich’s Ascites Carcinoma

Abstract

Sorafenib was the first multikinase inhibitor to be approved for use in metastatic renal cell carcinoma. Olmesartan medoxomil used in treatment of hypertension and was reported to inhibit angiogenesis in several models. The present study was designed to assess the safety of a combination of sorafenib plus olmesartan compared to monotherapies in mice bearing Ehrlich's ascites carcinoma cell line. Mice were divided to seven groups, 1) normal mice, 2) Ehrlich's ascites carcinoma control, 3-5) olmesartan (3, 10, 30 mg/kg/day), respectively, 6) sorafenib (30 mg/kg/day) and 7) the combination group: mice received olmesartan (30 mg/kg/day) plus sorafenib. All drug treatments continued for 21 days. At the end of the experiment, a complete blood count was performed and kidney and liver functions were estimated. The combination therapy produced a non-significant change in most of the measurements of complete blood count and liver enzymes when compared to normal animals. On the other hand, the combined therapy significantly increased blood urea nitrogen when compared to normal group but did not change the serum creatinine level. Concomitant administration of olmesartan with sorafenib did not significantly augment the toxicity of the later. Therefore; olmesartan might be a safe candidate with sorafenib in treatment of cancer if clinical data proved the benefit of this combination.

The effects of sorafenib in healthy and cisplatin-treated rats

“…It has also been reported that sorafenib increases ALT and AST, thereby inducing liver damage. 20,22 However, there is no information about how IL-38 levels progress with subsequent applications. The IL-38, a member of the IL-1 family with pro-inflammatory and antiinflammatory effects, is expressed in different tissues, such as the heart, placenta, fetal liver, spleen, thymus, and tonsils, and is generally associated with rheumatic diseases.…”

Rosmarinic acid suppresses inflammation, angiogenesis, and improves paclitaxel induced apoptosis in a breast cancer model via NF3 κB-p53-caspase-3 pathways modulation

“…Ascitic fluid of Ehrlich ascites carcinoma-infected mice was withdrawn then mixed with normal saline to form a suspension of 2 × 10 6 cells and used as a source of Ehrlich carcinoma cells (Katary et al, 2019). The viability of cells were checked by a Trypan blue dye exclusion assay (Abd-Alhaseeb et al, 2013).…”